REG - Arecor Therapeutics - Change of Auditor

Arecor TherapeuticsAnnouncement

08/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250808:nRSH5039Ua&default-theme=true

RNS Number : 5039U  Arecor Therapeutics PLC  08 August 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

CHANGE OF AUDITOR

 

Cambridge, UK, 8 August 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces that following the conclusion of a formal tender
process led by the Company's Audit and Risk Committee, the Board has approved
the appointment of PKF Littlejohn LLP ("PKF") as the Company's auditor,
succeeding Grant Thornton UK LLP ("GT").

 

GT ceases to hold office as the Company's auditor and has confirmed there are
no matters that need to be brought to the attention of the members or
creditors of the Company.

 

PKF will conduct the audit of the Company's financial statements for the
financial year ending 31 December 2025. The appointment of PKF as auditor for
the following financial year will be subject to approval by the shareholders
at the 2026 Annual General Meeting of the Company.

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPDGGDIUBGDGUR